DOSAGE INDEX / SINGLE
AOD-9604
Research, reported schedules and supply planning.
Examine AOD-9604 human obesity results, animal fat-metabolism studies, GH fragment identity, safety reporting and joint-repair claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 300–500 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–28 | 0.3 mg | Daily |
| Days 29–84 | 0.5 mg | Daily |
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Acidic diluent / GA water: under formulation review. Acetic-acid concentration, glycerin content, peptide salt form and intended laboratory use must be specified before compatibility can be assessed. No acidic diluent has been assigned to this product or blend.
Vial comparison
Source example: 84-day planning window: 36.4 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 2 mg | 19 |
| 5 mg | 8 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- FDA's December 2024 briefing describes the OPTIONS trial as randomizing 502 adults with obesity to oral AOD-9604 or placebo, alongside a diet and exercise program. The primary weight-loss comparison did not show a significant difference. The assessment also records that the developer terminated obesity development in 2007 after results did not support commercial viability. [2]
- A 2000 experiment gave oral AOD-9604 to obese Zucker rats for 19 days. Treated animals gained 15.8 grams compared with 35.6 grams in controls. The researchers also reported increased lipolytic activity in adipose tissue and no adverse effect on insulin sensitivity in the tested model. [3]
- The 2024 FDA assessment identifies insufficient information about long-term safety and the proposed subcutaneous and transdermal uses. It raises concerns about impurities and aggregation. It also describes serious events in the clinical summaries while emphasizing inadequate information to assess causation, particularly for reported cancers. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 22 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original detection and metabolism study
- FDA assessment of the clinical program
- Original rat metabolic study
- Original mouse study
- Original human safety publication
- Original nonclinical safety and metabolism report
- Original rabbit joint study
- Bachem: peptide solubility and handling guidance (laboratory methods)
- Journal of Endocrinology and Metabolism (2014)Further reading · Listed in reference bibliography.
- MedlinePlus Medical Encyclopedia (NIH)General guidance · Listed in reference bibliography.
- Endocrinology (OUP)Further reading · Listed in reference bibliography.
- GastroenterologyFurther reading · Listed in reference bibliography.
- DrugBankFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.